Literature DB >> 2137299

Chronic inhibition of fatty acid oxidation: new model of diastolic dysfunction.

S E Litwin1, T E Raya, R G Gay, J B Bedotto, J J Bahl, P G Anderson, S Goldman, R Bressler.   

Abstract

This study was designed to determine the changes in the heart that result from inhibition of long-chain fatty acid oxidation with 2-tetradecylglycidic acid (TDGA). Male Sprague-Dawley rats (n = 64) were treated with TDGA (20 mg.kg-1.day-1) or a comparable volume of vehicle by gavage feeding for 7 or 21 days. In conscious rats TDGA produced no changes in heart rate, left ventricular systolic or end-diastolic pressures, left ventricular pressure development (dP/dt), or the time constant of left ventricular relaxation. Left ventricular developed pressure was not changed at 21 days. TDGA increased left ventricular weight, left ventricular weight-to-body weight ratio, and total heart weight-to-body weight ratio. Left ventricular endocardial and epicardial myocyte volumes were increased by 53 and 65%, respectively. Myocardial triglyceride content was increased threefold. Left ventricular chamber stiffness constants between end-diastolic pressures of 0 and 30 mmHg were increased, and left ventricular end-diastolic volumes at operating end-diastolic pressures were decreased at both 7 and 21 days. The myocardial stiffness constant was also increased at 7 and 21 days. Thus inhibition of long-chain fatty acid oxidation with TDGA increased left ventricular mass and altered left ventricular chamber and muscle stiffness without changing left ventricular relaxation or systolic function. We conclude that inhibition of long-chain fatty acid oxidation produced an unusual model of left ventricular hypertrophy and diastolic dysfunction characterized by abnormalities of passive-elastic properties but preserved relaxation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137299     DOI: 10.1152/ajpheart.1990.258.1.H51

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

Review 1.  Correction of dysfunctional fatty acid metabolism using peroxisome proliferator activated receptor gamma agonists.

Authors:  Nicholas D Oakes; Bengt Ljung; Germán Camejo
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

2.  Effect of prolonged treatment with propionyl-L-carnitine on erucic acid-induced myocardial dysfunction in rats.

Authors:  E Pasini; A Cargnoni; E Condorelli; A Marzo; R Lisciani; R Ferrari
Journal:  Mol Cell Biochem       Date:  1992-06-26       Impact factor: 3.396

Review 3.  Free fatty acid metabolism during myocardial ischemia and reperfusion.

Authors:  S C Hendrickson; J D St Louis; J E Lowe; S Abdel-aleem
Journal:  Mol Cell Biochem       Date:  1997-01       Impact factor: 3.396

4.  Modification of left ventricular hypertrophy by chronic etomixir treatment.

Authors:  M Turcani; H Rupp
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

5.  Functional and metabolic effects of propionyl-L-carnitine in the isolated perfused hypertrophied rat heart.

Authors:  R Motterlini; M Samaja; M Tarantola; R Micheletti; G Bianchi
Journal:  Mol Cell Biochem       Date:  1992-10-21       Impact factor: 3.396

6.  Mouse SIRT3 attenuates hypertrophy-related lipid accumulation in the heart through the deacetylation of LCAD.

Authors:  Tongshuai Chen; Junni Liu; Na Li; Shujian Wang; Hui Liu; Jingyuan Li; Yun Zhang; Peili Bu
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

Review 7.  Significance of Levocarnitine Treatment in Dialysis Patients.

Authors:  Hiroyuki Takashima; Takashi Maruyama; Masanori Abe
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

8.  Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model--the Zucker diabetic rat.

Authors:  Fabien Forcheron; Alexandra Basset; Pauline Abdallah; Peggy Del Carmine; Nicolas Gadot; Michel Beylot
Journal:  Cardiovasc Diabetol       Date:  2009-03-24       Impact factor: 9.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.